Starpharma's DEO shows reduced neurotoxicity
14 October, 2013 by Dylan Bushell-EmblingStarpharma's (ASX:SPL) DEO, a formulation of colon and colorectal cancer drug oxaliplatin, has demonstrated reduced neurotoxicity in lab trials comparing it to the original version.
Melbourne Uni licenses Parkinson's tech to start-up
11 October, 2013 by Dylan Bushell-EmblingResearch from the University of Melbourne and the Florey Institute could be developed into a new class of drugs for neurodegenerative diseases.
Novogen acquires cancer drug tech from Genscreen
10 October, 2013 by Dylan Bushell-EmblingNovogen (ASX:NRT) has licensed Australian-developed drug technology with the potential to replace the popular class of chemotherapeutics that target the cytoskeleton of cancer cells.
2013 Victoria Prize rewards malaria researcher
10 October, 2013Professor Alan Cowman from the Walter and Eliza Hall Institute has been awarded the 2013 Victoria Prize for Science and Innovation in recognition of his outstanding contributions in the quest to eradicate malaria.
UQ and LEO Pharma collaborate on skin cancer treatment
10 October, 2013The University of Queensland (UQ) and global pharmaceutical company LEO Pharma have entered a strategic research collaboration to deliver new treatment options to skin cancer patients.
Bionomics' extra overseas expenses eligible for R&D Tax Incentive
08 October, 2013Bionomics (ASX:BNO) has received additional decisions from Innovation Australia in relation to the company's applications for an advance finding under the R&D Tax Incentive.
Clinical Genomics acquires cancer-screening lab Enterix
08 October, 2013Clinical Genomics recently acquired the US-based cancer screening company Enterix.
The 2013 Nobel Prize in Physiology or Medicine
08 October, 2013Three scientists' work on a major transport system in cells has won them the 2013 Nobel Prize in Physiology or Medicine.
Mental Health Research Alliance
04 October, 2013Queensland's key health research institutes have joined forces to create the Queensland Mental Health Research Alliance.
GTG completes $3m share purchase plan
04 October, 2013 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) has completed the SPP stage of its capital raising and revealed that underwriter Cygnetl has committed to buy an extra $1m worth of shares.
Prima re-evaluating CVac trial design
04 October, 2013 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) is re-evaluating using PFS as a primary objective of an upcoming trial of its CVac cancer immunotherapy candidate, based on results to date of an earlier study.
Former Alchemia CEO joins Ascend as chairman
03 October, 2013 by Dylan Bushell-EmblingDr Peter Smith, former CEO of Alchemia (ASX:ACL), has joined Ascend Biopharmaceuticals as its board chairman.
Research Alliance calls for strategic research policy
02 October, 2013Research Alliance advocates for science, research and innovation to have steady and purposeful support.
Vic biotechs win out in Technology Voucher program
27 September, 2013 by Dylan Bushell-EmblingThe Victorian Government has awarded Technology Development vouchers worth up to $50K for 10 high-tech projects, including research into potential treatments for Crohn's disease.
Linking immunity and cancer progression
27 September, 2013An explanation for how a subset of ovarian cancers block the body's early anti-tumour immune response may expand treatment options for patients.
